Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Somira Health vs YourHealthRx

Somira Health
Graded #269

Lower grade

vs+7.099999999999994
YourHealthRx
Graded #119

Higher grade

The verdict

YourHealthRx takes it — 69.6/100 to 62.5/100.

YourHealthRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. YourHealthRx is a scientist-founded peptide and GLP-1 telehealth platform available in all 50 states and DC via a multi-state (IMLC) clinician network.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueYourHealthRx +1
52
53
Dose & formulationYourHealthRx +11
64
75
Clinical oversightYourHealthRx +10
77
87
Labs & monitoringYourHealthRx +5
62
67
FulfillmentYourHealthRx +11
83
94
Contract termsYourHealthRx +8
25
33
Somira Health · left barYourHealthRx · right bar

The numbers

MetricSomira HealthYourHealthRx
WeighScore62.5/10069.6/100
GradeCC
Scorecard rank#269#119
Semaglutide$190/mo (compounded)$170/mo (compounded)
Tirzepatide$285/mo (compounded)$210/mo (compounded)
CoverageCoverage not publishedAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyYes
Somira Health

Graded #269 · C

Strengths

  • Transparent flat monthly pricing that does not increase as you titrate (semaglutide $189.99/mo, tirzepatide $284.99/mo)
  • Quarterly plans lower the effective monthly cost (semaglutide $136.66/mo, tirzepatide $221.66/mo)
  • Free overnight shipping, with syringes and alcohol wipes included in every order
  • Simple, fast online intake reviewed by a licensed provider; no insurance required
  • Both weekly compounded GLP-1 options offered: semaglutide and tirzepatide

Where it loses points

  • Compounded medications are not FDA-approved (the site discloses this) — not brand Wegovy, Ozempic, Zepbound, or Mounjaro
  • The compounding pharmacy partner is not named
  • State-availability list is not published
  • No LegitScript certification displayed
  • New, thin platform with limited public detail on the provider network, lab monitoring, or ongoing support
YourHealthRx

Graded #119 · C

Strengths

  • Available in all 50 states and DC through a multi-state (IMLC) licensed clinician network
  • Compounded semaglutide and tirzepatide in two formats - weekly injectable (with B12) or daily oral dissolving tablet
  • Flat subscription price that doesn't change as your dose increases (no titration penalty)
  • Science-forward, clinician-led, with built-in follow-up, lab testing, and a broad peptide and longevity catalog (BPC-157, TB-500, sermorelin, NAD+)
  • Transparent, education-first positioning with published medical disclaimer, privacy, and terms

Where it loses points

  • Eligibility and prescribing run through partner clinical workflows - YourHealthRx is the platform, not the prescriber or pharmacy
  • Compounded medications are not FDA-approved - not brand Wegovy, Ozempic, Zepbound, or Mounjaro
  • The compounding pharmacy partner is not named ('transparent sourcing' claimed but no pharmacy disclosed)
  • Headline prices include a first-month intro rate; ongoing monthly cost is higher (semaglutide ~$170, tirzepatide ~$210)
  • No LegitScript certification displayed

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard